Clinical outcomes of dupilumab therapy in chronic rhinosinusitis with nasal polyps in a Canadian tertiary care rhinology practice

BACKGROUND: In 2020, dupilumab became the first monoclonal antibody therapy to be approved by Health Canada for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). The primary aim of this study was to characterize the outcomes in an initial cohort of patients with CRSwNP who have und...

Descripción completa

Detalles Bibliográficos
Autores principales: Grose, Elysia, Li, Alyssa Y., Lee, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061739/
https://www.ncbi.nlm.nih.gov/pubmed/36998065
http://dx.doi.org/10.1186/s13223-023-00782-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061739/
https://www.ncbi.nlm.nih.gov/pubmed/36998065
http://dx.doi.org/10.1186/s13223-023-00782-7

Ejemplares similares